Skip to main content
PEP-TA1-KPV • RESEARCH USE ONLY

Thymosin Alpha-1 / KPV

A dual-action nasal peptide blend combining Thymosin Alpha-1 (TA-1), a powerful immune-modulating thymic peptide, with KPV, a potent anti-inflammatory and immune-calming tripeptide. Together, they promote balanced immune function, reduced inflammation, and whole-body resilience.

10 mg / 10 mg

Per Bottle
62 mcg / 62 mcg per spray

>99%

Purity
Third-party verified

160

Sprays per bottle

Disclaimer: Dosing guides are provided as suggestions for prescribed use only in countries where the use of the respective peptides is legally permitted. These guides have not been approved by any regulatory authority and are not intended to constitute medical advice.

Protocol & Dosing

Use once daily for general immune support. During periods of high immune demand (travel, illness exposure, recovery, high stress), dosing may be increased to twice daily. This combination does not require fasted dosing and may be taken with or without food; food does not reduce immune-modulating effectiveness. Designed for ongoing immune support when properly cycled.

Starting
125 mcg / 125 mcg (2 sprays)
Medium
250 mcg (4 sprays)
Higher
375 mcg (6 sprays)
Cycles
  • Use for 8–12 weeks
  • Take 1 week off after each cycle to optimize immune and receptor responsiveness
Key Benefits

Strengthens immune defense, supports immune balance, calms systemic inflammation, supports healthy skin and gut integrity, enhances recovery from stress or illness, and promotes overall vitality and resilience.

Guidance
  • Start with 2 sprays once daily
  • Increase gradually only if needed
  • May split dosing morning / evening during high immune demand
  • Do not exceed 6 sprays per day unless directed
  • KPV can cause excessive immune suppression if used too frequently
  • Ideal for immune resilience, inflammation control, skin support, and recovery
  • Well tolerated and non-stimulatory
  • Pairs well with BPC-157, GHK-Cu, Vitamin D3, and Zinc for comprehensive immune and regenerative support
PROPRIETARY DELIVERY TECHNOLOGY

Zenith Nano™ Spray System

Nasal delivery is facilitated with the Zenith Nano™ Spray System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange
Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.
Dual-polarity solubilization
Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.
Keratin modulation & partitioning
Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).
Superior loading vs. lipid carriers
Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Zenith Nano™ Spray System reaches therapeutically relevant layers.
>57× vs. saline · <10 nm (DLS)
>57× barrier penetration vs. saline in an ex vivo epithelial model (Zenith Nano™ third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.
Safety, stability & distribution
ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Zenith Nano™ Peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117
Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA